ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, these findings demonstrate that the inhibition of USP14 and UCHL5 may kill TKI‐sensitive and ‐resistant CML cells through downregulating BCR‐ABL levels.